Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines 
in medicine, such as oncology, rheumatology, gastroenterology, dermatology and 
transplant rejection prevention. Since the introduction and reintroduction of 
the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained 
relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs 
have been tested in clinical trials in relapsing-remitting MS, and in 
progressive forms of MS. One of the agents that might soon be approved for very 
active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against 
CD52. This review provides insights into clinical studies with the mAbs 
natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.